Luchino Chessa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6928669/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Long-term benefit of interferon $\hat{l}\pm$ therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology, 2004, 126, 1740-1749.	1.3	288
2	Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3081-3086.	7.1	195
3	Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut, 2013, 62, 290-298.	12.1	105
4	Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Frontiers in Immunology, 2020, 11, 605688.	4.8	92
5	Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clinical Practice and Epidemiology in Mental Health, 2007, 3, 22.	1.2	72
6	Association of chronic hepatitis C with recurrent brief depression. Journal of Affective Disorders, 2012, 141, 361-366.	4.1	48
7	Treatment of chronic hepatitis D. Journal of Viral Hepatitis, 2007, 14, 58-63.	2.0	42
8	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.	2.5	37
9	Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0255608.	2.5	34
10	Forecasting Hepatitis C liver disease burden on realâ€life data. Does the <i>hidden iceberg</i> matter to reach the elimination goals?. Liver International, 2018, 38, 2190-2198.	3.9	33
11	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100248.	4.9	33
12	Exploring the Role of Killer Cell Immunoglobulin-Like Receptors and Their HLA Class I Ligands in Autoimmune Hepatitis. PLoS ONE, 2016, 11, e0146086.	2.5	26
13	Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management. Expert Review of Gastroenterology and Hepatology, 2021, 15, 41-50.	3.0	26
14	Modeling costâ€effectiveness and health gains of a "universal―versus "prioritized―hepatitis C virus treatment policy in a realâ€life cohort. Hepatology, 2017, 66, 1814-1825.	7.3	25
15	Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. Journal of Hepatology, 2018, 68, 33-41.	3.7	19
16	Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5Âmonths after vaccination. Clinical and Experimental Medicine, 2022, 22, 477-485.	3.6	18
17	Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. Digestive and Liver Disease, 2012, 44, 674-680.	0.9	17
18	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	8.1	15

LUCHINO CHESSA

#	Article	IF	CITATIONS
19	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. Journal of Hepatology, 2021, 75, 1355-1366.	3.7	15
20	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori, 2018, 104, 476-479.	1.1	14
21	A prospective study of directâ€acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology, 2022, 76, 220-232.	7.3	12
22	Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. Scandinavian Journal of Gastroenterology, 2019, 54, 1274-1282.	1.5	11
23	Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin. Haematologica, 2006, 91, ECR26.	3.5	10
24	Evaluation of humoral and cellular response to third dose of BNT162b2 mRNA COVID-19 vaccine in patients treated with B-cell depleting therapy. Journal of Autoimmunity, 2022, 131, 102848.	6.5	10
25	Absence of activating killer immunoglobulin-like receptor genes combined with hepatitis C viral genotype is predictive of hepatocellular carcinoma. Human Immunology, 2013, 74, 1288-1294.	2.4	9
26	Previous Functional Social and Behavioral Rhythms Affect Resilience to Covid-19-Related Stress among Old Adults. Journal of Public Health Research, 2022, 11, jphr.2022.2768.	1.2	9
27	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. Hepatology International, 2020, 14, 362-372.	4.2	8
28	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65Âyears with HCV genotype 1 cirrhosis. Infection, 2018, 46, 607-615.	4.7	7
29	Entropy of human leukocyte antigen and killer-cell immunoglobulin-like receptor systems in immune-mediated disorders: A pilot study on multiple sclerosis. PLoS ONE, 2019, 14, e0226615.	2.5	6
30	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Digestive and Liver Disease, 2021, 53, 612-619.	0.9	6
31	Review article: safety of new biologic agents for inflammatory bowel disease in the liver. European Journal of Gastroenterology and Hepatology, 2021, 33, 623-630.	1.6	5
32	The Covid-19 Incidence in Italian Regions Correlates with Low Temperature, Mobility and Pm10 Pollution but Lethality Only with Low Temperature. Journal of Public Health Research, 2021, 10, jphr.2021.2303.	1.2	5
33	Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination. Vaccines, 2022, 10, 531.	4.4	5
34	Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. Vaccines, 2021, 9, 1478.	4.4	5
35	Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?. Blood, 2006, 107, 3409-3410.	1.4	4
36	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. BMC Infectious Diseases, 2017, 17, 734.	2.9	4

LUCHINO CHESSA

#	Article	IF	CITATIONS
37	The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. Journal of Ultrasound, 2016, 19, 91-98.	1.3	3
38	Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?. HIV Clinical Trials, 2018, 19, 188-196.	2.0	3
39	HepaDisk – A new quality of life questionnaire for HCV patients. Digestive and Liver Disease, 2019, 51, 1008-1015.	0.9	3
40	COVID-19: Considerations about immune suppression and biologicals at the time of SARS-CoV-2 pandemic. World Journal of Clinical Cases, 2021, 9, 5352-5357.	0.8	3
41	Safety and Efficacy of Direct-Acting Antivirals in Transfusion-Dependent Thalassemic Patients with Chronic Hepatitis C. Hepatitis Monthly, 2018, 18, .	0.2	3
42	A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population. Frontiers in Immunology, 2022, 13, 891147.	4.8	3
43	Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. Journal of Immigrant and Minority Health, 2017, 19, 876-882.	1.6	2
44	Impact of direct-acting antiviral drugs for chronic hepatitis C on mood: Preliminary results from a longitudinal study. General Hospital Psychiatry, 2019, 56, 50-51.	2.4	2
45	Can Antiretroviral Therapy Modify the Clinical Course of HDV Infection in HIV-Positive Patients?. Antiviral Therapy, 2015, 20, 671-679.	1.0	1
46	F-7 Insulin resistance does not affect sustained virologic response in patients with chronic hepatitis C without cirrhosis treated with peg-interferon alfa 2a and ribavirin. Digestive and Liver Disease, 2011, 43, S94.	0.9	0
47	F-51 Virological response and HBV-DNA reduction during therapy with peginterferon alpha-2a (PEC-IFNα-2a) in patients affected by HBeAg-negative chronic hepatitis B. Digestive and Liver Disease, 2012, 44, S48.	0.9	0
48	P-387 - Psychopatological symptoms and quality of life in patients receiving interferon: Results of a prospective study. European Psychiatry, 2012, 27, 1.	0.2	0
49	Association of IFNL4 genotype and ALT decrease is a new tool to predict viral eradication in HCV Sardinian patients with chronic hepatitis C, genotype 4, treated with PEG-IFNα and Ribavirin. Digestive and Liver Disease, 2014, 46, e48-e49.	0.9	0
50	Oral bacterial load in autoimmune liver diseases: possible role or coincidence?. Digestive and Liver Disease, 2015, 47, e65.	0.9	0
51	Role of Killer cell immunoglobulin-like receptors and their HLA class I ligands in autoimmune hepatitis. Digestive and Liver Disease, 2015, 47, e29.	0.9	0
52	Transient elastography in patients with chronic autoimmune hepatitis: is a good tool in evaluation of hepatic fibrosis?. Digestive and Liver Disease, 2015, 47, e64.	0.9	0
53	Covid-19 vaccines work but other factors play a relevant role: a data analysis on spread and mortality in 24 countries. Journal of Public Health Research, 2022, 11, .	1.2	0
54	Verifying the Theory of Climate Affecting Lethality of COVID-19 by an Analysis in Two Climatic Zones of Chile. Open Public Health Journal, 2022, 15, .	0.4	0